• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRIâ„¢ Website
      • ISPRI Downselectâ„¢
      • ISPRI Quantifyâ„¢
      • ISPRI Analyzeâ„¢
      • ISPRI Evaluateâ„¢
      • ISPRI-HCPâ„¢
      • ISPRI Designâ„¢
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAXâ„¢
      • EpiCCâ„¢
      • Ancer®
      • PreVAXâ„¢
    • Lab Services
      • All In Vitro Assays
      • Generic Peptide PANDA® Assays
    • Consulting Services
      • Trusted Expert Advice (TEA)
      • IRA / ISI Regulatory Writing Support
  • About Us
    • Leadership
    • Careers
  • Partner
  • Press
    • News
    • Events
    • Publications
    • Blog
  • Contact Us
Quantifying the Persistence of Vaccine-related T cell Epitopes in Circulating Swine Influenza A Strains from 2013-2017

Quantifying the Persistence of Vaccine-related T cell Epitopes in Circulating Swine Influenza A Strains from 2013-2017

by Elena Iemma | Mar 23, 2021

Quantifying the Persistence of Vaccine-related T cell Epitopes in Circulating Swine Influenza A Strains from 2013-2017
New Immunoinformatics Tools for Swine: Designing Epitope-Driven Vaccines, Predicting Vaccine Efficacy, and Making Vaccines on Demand

New Immunoinformatics Tools for Swine: Designing Epitope-Driven Vaccines, Predicting Vaccine Efficacy, and Making Vaccines on Demand

by Elena Iemma | Oct 5, 2020

T-cell epitope content comparison (EpiCC) of swine H1 influenza A virus hemagglutinin

T-cell epitope content comparison (EpiCC) of swine H1 influenza A virus hemagglutinin

by Sarah Moniz | Dec 19, 2017

The two-faced T cell epitope: Examining the host-microbe interface with JanusMatrix

The two-faced T cell epitope: Examining the host-microbe interface with JanusMatrix

by Adam | Oct 22, 2016

Hum Vaccin Immunother. 2013 Apr 12;9(7). PubMed PMID 23584251
Cross-conservation of T-cell epitopes: now even more relevant to (H7N9) influenza vaccine design

Cross-conservation of T-cell epitopes: now even more relevant to (H7N9) influenza vaccine design

by Adam | Oct 22, 2016

Hum Vaccin Immunother. 2014 Feb Full Text
« Older Entries
Next Entries »

Recent Posts

  • Immunogenicity Risk Assessment Outputs to Drive a Streamlined, Risk-Based Preclinical and Clinical Strategy 
  • BEBPA Workshop: Streamlining Immunogenicity Assessment of Host Cell Proteins
  • Advancing Immunogenicity Science: EpiVax in 2025 
  • EpiVax Supports Life-Saving Programs Through Partnerships with GAIA Vaccine Foundation and Clínica Esperanza/Hope Clinic
  • EpiVax and FDA Scientists Publish New Insights on Immunogenicity Risks of Peptide-Related Impurities in Generic Teriparatide

Recent Comments

No comments to show.

Join our newsletter

Stay up to date with EpiVax and greater industry news, events, and technological advancements with this monthly update written by EpiVax co-founder and CMO, Dr. Annie De Groot.

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

LinkedIn

About Us

Careers

Partner

News

Events

Publications

Contact Us

We use cookies to ensure that we give you the best experience on our website. By clicking 'accept', you consent to our use of cookies.